Search

Your search keyword '"Burgos-Vargas R"' showing total 513 results
Start Over Author "Burgos-Vargas R"
513 results on '"Burgos-Vargas R"'

1. Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (SJIA): tender 52-week data

Author

Espada G, Pardeo M, Chaitow J, Brown D, Allen R, Zulian F, Zuber Z, Wulffraat N, Joos R, Dolezalova P, Burgos-Vargas R, Woo P, Schneider R, Ruperto N, Brunner H, De Benedetti F, Flato B, Gerloni V, Horneff G, Wright S, Kenwright A, Lovell D, and Martini A

Subjects
Pediatrics, RJ1-570, Diseases of the musculoskeletal system, RC925-935
Published
2011
Full Text
View/download PDF

2. Differences in therapeutic approach to juvenile dermatomyositis between Europe and Latin America

Author

Trail L, Ferrari C, Cuttica R, Katsicas MM, Russo R, Bandeira M, Ferriani V, Oliveira S, Saad-Magalhaes C, Silva CA, Baca V, Burgos-Vargas R, Solis-Vallejo E, Maillard S, Pilkington C, Barcellona R, Beltramelli M, Breda L, Bruno C, Cimaz R, Cortis E, Gallizzi R, Garofalo F, Meini A, Podda R, Stabile A, Martini A, and Ravelli A

Subjects
Pediatrics, RJ1-570, Diseases of the musculoskeletal system, RC925-935
Published
2008
Full Text
View/download PDF

4. 8.5 Predictors of long-term outcome of Juvenile Dermatomyositis (JDM): a Multicenter, Multinational Study of 490 patients

Author

Ferrari C, Trail L, Pilkington C, Maillard S, Cuttica R, Katsicas MM, Russo R, Bandeira M, Ferriani V, Oliveira S, Saad-Magalhaes C, Silva CA, Baca V, Burgos-Vargas R, Solis-Vallejo E, Alessio M, Alpigiani MG, Corona F, Falcini F, Gerloni V, Lepore L, Magni-Manzoni S, Zulian F, Ruperto N, Pistorio A, Felici E, Rossi F, Sala E, Martini A, and Ravelli A

Subjects
Pediatrics, RJ1-570, Diseases of the musculoskeletal system, RC925-935
Published
2008
Full Text
View/download PDF

6. A randomized, double-blind, placebo-controlled 12-week trial of infliximab in patients with juvenile-onset spondyloarthritis

Author

Burgos-Vargas, R., Loyola-Sanchez, A., Ramiro, S., Reding-Bernal, A., Alvarez-Hernandez, E., Heijde, D. van der, and Vazquez-Mellado, J.

Subjects
Adolescent, Active joint counts, Arthritis, Juvenile, Infliximab, C-Reactive Protein, Treatment Outcome, Double-Blind Method, Antirheumatic Agents, Spondylarthritis, Spondyloarthritis, Humans, Spondylitis, Ankylosing, Randomized trial, Child, Open-label study, Juvenile SpA
Abstract

Objective To assess the efficacy and safety of infliximab versus placebo in the treatment of patients with juvenile-onset spondyloarthritis (JoSpA). Methods Phase III, randomized, double-blind, placebo-controlled trial of 12 weeks that included patients ≤ 18 years old with JoSpA not responding to nonsteroidal anti-inflammatory drugs, sulfasalazine, or methotrexate. Patients were randomly assigned 1:1 to the infusion of infliximab 5mg/kg or placebo; completers entered then an open-label extension (OLE) period of 42 weeks. The primary endpoint was the number of active joints. Secondary outcomes included the assessment of disease activity, tender entheses, spinal mobility, serum C-reactive protein (CRP), the Bath Ankylosing Spondylitis Disease Activity and Functional Index, and the Childhood Health Assessment Questionnaire (CHAQ). Results We randomized 12 patients to infliximab and 14 to placebo. No significant differences were found between groups at baseline. At week 12, the mean number of active joints was 1.4 (SD 2.4) in the infliximab group and 4.1 (SD 3.0) in the placebo group (p = 0.0002). A repeated-measures mixed model analysis that included all endpoints in the study demonstrated sustained favourable outcomes of infliximab for active joints, tender joints, swollen joints, and tender enthesis counts, as well as for CHAQ and CRP (p < 0.01). Adverse events were more frequent in the infliximab group, including infections and infusion reactions, but none of them was serious. Conclusion Infliximab is efficacious for patients with JoSpA with an inadequate response to conventional treatment. No serious adverse events with the use of infliximab were observed.

Published
2022

7. PREDICTORS OF CLINICAL RESPONSE TO ABATACEPT IN CHILDREN WITH POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS

Author

Ruperto, N., Brunner, H., Berman, A., Zapata, F. Avila, Horneff, G., Wagner-Weiner, L., Belot, A., Burgos-Vargas, R., Gamir Gamir, M. L., Goldenstein-Schainberg, C., Terreri, M. T., Askelson, M., Wong, R., Martini, A., Lovell, D. J., Ruperto, N., Brunner, H., Berman, A., Zapata, F. Avila, Horneff, G., Wagner-Weiner, L., Belot, A., Burgos-Vargas, R., Gamir Gamir, M. L., Goldenstein-Schainberg, C., Terreri, M. T., Askelson, M., Wong, R., Martini, A., and Lovell, D. J.

Published
2022

8. OP0216 DEVELOPMENT, REFINEMENT AND WEIGHTING OF CANDIDATE CRITERIA FOR AXIAL DISEASE IN JUVENILE SPONDYLOARTHRITIS: AN INTERNATIONAL COLLABORATION

Author

Weiss, P. F., primary, Brandon, T. G., additional, Aggarwal, A., additional, Burgos-Vargas, R., additional, Colbert, R. A., additional, Horneff, G., additional, Joos, R., additional, Laxer, R., additional, Minden, K., additional, Ravelli, A., additional, Ruperto, N., additional, Smith, J., additional, Stoll, M. L., additional, Tse, S. M., additional, van den Bosch, F., additional, Maksymowych, W. P., additional, Lambert, R. G., additional, Biko, D. M., additional, Chauvin, N. A., additional, Francavilla, M. L., additional, Jaremko, J. L., additional, Herregods, N., additional, Kasapcopur, O., additional, Yildiz, M., additional, and Hendry, A. M., additional

Published
2022
Full Text
View/download PDF

9. POS0340 PREDICTORS OF CLINICAL RESPONSE TO ABATACEPT IN CHILDREN WITH POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS

Author

Ruperto, N., primary, Brunner, H., additional, Berman, A., additional, Avila Zapata, F., additional, Horneff, G., additional, Wagner-Weiner, L., additional, Belot, A., additional, Burgos-Vargas, R., additional, Gámir Gámir, M. L., additional, Goldenstein-Schainberg, C., additional, Terreri, M. T., additional, Askelson, M., additional, Wong, R., additional, Martini, A., additional, and Lovell, D. J., additional

Published
2022
Full Text
View/download PDF

10. POS0173 DATA-DRIVEN MRI DEFINITIONS FOR ACTIVE AND STRUCTURAL SACROILIAC JOINT LESIONS IN JUVENILE SPONDYLOARTHRITIS TYPICAL OF AXIAL DISEASE

Author

Weiss, P. F., primary, Brandon, T. G., additional, Aggarwal, A., additional, Burgos-Vargas, R., additional, Colbert, R. A., additional, Horneff, G., additional, Joos, R., additional, Laxer, R., additional, Minden, K., additional, Ravelli, A., additional, Ruperto, N., additional, Smith, J., additional, Stoll, M. L., additional, Tse, S. M., additional, Van den Bosch, F., additional, Lambert, R. G., additional, Biko, D. M., additional, Chauvin, N. A., additional, Francavilla, M. L., additional, Jaremko, J. L., additional, Herregods, N., additional, Kasapcopur, O., additional, Yildiz, M., additional, Hendry, A. M., additional, and Maksymowych, W. P., additional

Published
2022
Full Text
View/download PDF

12. International Consensus for the Dosing of Corticosteroids in Childhood-Onset Systemic Lupus Erythematosus With Proliferative Lupus Nephritis

Author

Chalhoub, N.E. Wenderfer, S.E. Levy, D.M. Rouster-Stevens, K. Aggarwal, A. Savani, S.I. Ruth, N.M. Arkachaisri, T. Qiu, T. Merritt, A. Onel, K. Goilav, B. Khubchandani, R.P. Deng, J. Fonseca, A.R. Ardoin, S.P. Ciurtin, C. Kasapcopur, O. Jelusic, M. Huber, A.M. Ozen, S. Klein-Gitelman, M.S. Appenzeller, S. Cavalcanti, A. Fotis, L. Lim, S.C. Silva, R.M. Miramontes, J.R. Rosenwasser, N.L. Saad-Magalhaes, C. Schonenberg-Meinema, D. Scott, C. Silva, C.A. Enciso, S. Terreri, M.T. Torres-Jimenez, A.-R. Trachana, M. Al-Mayouf, S.M. Devarajan, P. Huang, B. Brunner, H.I. Abulaban, K. Aguiar, C. Ahn, S.-Y. Akoghlanian, S. Al-Abrawi, S. Aljaberi, N. Alperin, R. Angeles-Han, S. Ardalan, K. Bader-Meunier, B. Balboni, I. Barbar-Smiley, F. Baxter, S. Beary, J. Boneparth, A. Brakeman, P. Bridges, J. Burgos-Vargas, R. Cabral, D.A. Cameto, J. Carter, C. Chang, J. Chédeville, G. Chhakchhuak, C. Chiraseveenuprapund, P. Cifuentes Alvarado, M. Concannon, A. Cooper, J. Cron, R. De Carvalho, L.M. De Quattro, K. De Ranieri, D. Dizon, B. Donnelly Wrigley, C. Duong, M.D. Eberhard, A. Ede, K. Edelheit, B. Edens, C. Espada, G. Farhey, Y. Flores, F. Fritz, D. Ganguli, S. Gilbert, M. Gittar, P. Greenbaum, L. Grom, A. Gulati, G. Harry, O. Hayward, K. Henrickson, M. Hersh, A. Hiraki, L. Hiskey, M. Hoffmann, S. Hollander, M. Hom, C. Houk, L. Houk, J.B. Hsieh, E.W.Y. Hsu, J. Jensen, P. Joos, R. Jurado, R. Jusan Fiorot, F. Kallash, M. Kamphuis, S. Keltsev, V., (deceased) Khanna, S. Kim, S. Kimseng, K.J. Knight, A. Kunder, R. Lai, J. Laskin, B. Lewandowski, L. Lim, L. Linda, W.-W. Lo, M. Lovell, D. Luggen, M. Madison, J. Mansuri, A. Martin, L. Mason, S. Miller, M. Mina, R. Mohammed, A. Moncrieffe, H. Moorthy, L. Morgan, E. Mosquera, A. Muntel, E. Muscal, E. Myones, B. Nocton, J. Ogbu, E. Okamura, D. Olson, J. Orrock, J. Paim-Marques, L. Pain, C. Park, C. Patel, P. Pereira, M. Prado, R.D. Radhakrishna, S. Rheault, M. Ridgway, W. Riskalla, M. Ronis, T. Sadun, R. Sagcal-Gironella, A.C. Santos, M.C. Schikler, K. AL Suwairi, W. Siddiqi, N. Silva, M.F. Singh-Grewal, D. Smitherman, E. Smolewska, E. Son, M.B. Srinivasalu, H. Sule, S. Susic, G. Syed, R. Thatayatikom, A. Ting, T. Toth, M. Turnier, J. Vashisht, P. Vega Fernandez, P. Velasquez, M. von Scheven, E. Wahezi, D. Ware, A. Wu, E. Yan, J. Yildirim-Toruner, C. Zamparo, C. Zhang, Y. Lawson, E. for the Childhood Arthritis Rheumatology Research Alliance Lupus Nephritis Work Group the Pediatric Rheumatology European Society Lupus Working Party

Abstract

Objective: To develop a standardized steroid dosing regimen (SSR) for physicians treating childhood-onset systemic lupus erythematosus (SLE) complicated by lupus nephritis (LN), using consensus formation methodology. Methods: Parameters influencing corticosteroid (CS) dosing were identified (step 1). Data from children with proliferative LN were used to generate patient profiles (step 2). Physicians rated changes in renal and extrarenal childhood-onset SLE activity between 2 consecutive visits and proposed CS dosing (step 3). The SSR was developed using patient profile ratings (step 4), with refinements achieved in a physician focus group (step 5). A second type of patient profile describing the course of childhood-onset SLE for ≥4 months since kidney biopsy was rated to validate the SSR-recommended oral and intravenous (IV) CS dosages (step 6). Patient profile adjudication was based on majority ratings for both renal and extrarenal disease courses, and consensus level was set at 80%. Results: Degree of proteinuria, estimated glomerular filtration rate, changes in renal and extrarenal disease activity, and time since kidney biopsy influenced CS dosing (steps 1 and 2). Considering these parameters in 5,056 patient profile ratings from 103 raters, and renal and extrarenal course definitions, CS dosing rules of the SSR were developed (steps 3–5). Validation of the SSR for up to 6 months post–kidney biopsy was achieved with 1,838 patient profile ratings from 60 raters who achieved consensus for oral and IV CS dosage in accordance with the SSR (step 6). Conclusion: The SSR represents an international consensus on CS dosing for use in patients with childhood-onset SLE and proliferative LN. The SSR is anticipated to be used for clinical care and to standardize CS dosage during clinical trials. © 2021, American College of Rheumatology

Published
2022

13. Réponse échographique et clinique de l’atteinte des synovites chez les patients atteints de rhumatisme psoriasique traités par sécukinumab : résultats de l’étude ULTIMATE

Author

D’Agostino, M.A., primary, Conaghan, P., additional, Schett, G., additional, Mandl, P., additional, Naredo, E., additional, Van den Bosch, F., additional, Burgos-Vargas, R., additional, Duggan, A.M., additional, Goyanka, P., additional, Gaillez, C., additional, and Boers, M., additional

Published
2021
Full Text
View/download PDF

14. Identification of clinical phenotypes of peripheral involvement in patients with spondyloarthritis, including psoriatic arthritis

Author

Lopez-Medina, C., Chevret, S., Molto, A., Sieper, J., Duruoz, T., Kiltz, U., Elzorkany, B., Hajjaj-Hassouni, N., Burgos-Vargas, R., Maldonado-Cocco, J., Ziade, N., Gavali, M., Navarro-Compan, V., Luo, S.F., Biglia, A., Tae-Jong, K., Kishimoto, M., Pimentel-Santos, F.M., Gu, J.R., Muntean, L., Gaalen, F.A. van, Geher, P., Magrey, M., Ibanez-Vodnizza, S.E., Bautista-Molano, W., Maksymowych, W., Machado, P.M., Landewe, R., Heijde, D. van der, Dougados, M., Clinical Immunology and Rheumatology, and AII - Inflammatory diseases

Subjects
musculoskeletal diseases, Cross-Sectional Studies, Phenotype, ankylosing, arthritis, Arthritis, Psoriatic, Spondylarthritis, Spondyloarthritis, Cluster Analysis, Humans, spondylitis, psoriatic
Abstract

Objective To identify clusters of peripheral involvement according to the specific location of peripheral manifestations (ie, arthritis, enthesitis and dactylitis) in patients with spondyloarthritis (SpA) including psoriatic arthritis (PsA), and to evaluate whether these clusters correspond with the clinical diagnosis of a rheumatologist. Methods Cross-sectional study with 24 participating countries. Consecutive patients diagnosed by their rheumatologist as PsA, axial SpA or peripheral SpA were enrolled. Four different cluster analyses were conducted: one using information on the specific location from all the peripheral manifestations, and a cluster analysis for each peripheral manifestation, separately. Multiple correspondence analyses and k-means clustering methods were used. Distribution of peripheral manifestations and clinical characteristics were compared across the different clusters. Results The different cluster analyses performed in the 4465 patients clearly distinguished a predominantly axial phenotype (cluster 1) and a predominantly peripheral phenotype (cluster 2). In the predominantly axial phenotype, hip involvement and lower limb large joint arthritis, heel enthesitis and lack of dactylitis were more prevalent. In the predominantly peripheral phenotype, different subgroups were distinguished based on the type and location of peripheral involvement: a predominantly involvement of upper versus lower limbs joints, a predominantly axial enthesitis versus peripheral enthesitis, and predominantly finger versus toe involvement in dactylitis. A poor agreement between the clusters and the rheumatologist € s diagnosis as well as with the classification criteria was found. Conclusion These results suggest the presence of two main phenotypes (predominantly axial and predominantly peripheral) based on the presence and location of the peripheral manifestations.

Published
2021
Full Text
View/download PDF

15. Gout, Hyperuricemia, and Crystal-Associated Disease Network Consensus Statement Regarding Labels and Definitions for Disease Elements in Gout

Author

Bursill, D, Taylor, W, Terkeltaub, R, Kuwabara, M, Merriman, T, Grainger, R, Pineda, C, Louthrenoo, W, Edwards, N, Andres, M, Vargas-Santos, A, Roddy, E, Pascart, T, Lin, C, Perez-Ruiz, F, Tedeschi, S, Kim, S, Harrold, L, Mccarthy, G, Kumar, N, Chapman, P, Tausche, A, Vazquez-Mellado, J, Gutierrez, M, da Rocha Castelar-Pinheiro, G, Richette, P, Pascual, E, Fisher, M, Burgos-Vargas, R, Robinson, P, Singh, J, Jansen, T, Saag, K, Slot, O, Uhlig, T, Solomon, D, Keenan, R, Scire, C, Biernat-Kaluza, E, Dehlin, M, Nuki, G, Schlesinger, N, Janssen, M, Stamp, L, Sivera, F, Reginato, A, Jacobsson, L, Liote, F, H. -K., E, Rosenthal, A, Bardin, T, Choi, H, Hershfield, M, Czegley, C, Choi, S, Dalbeth, N, Bursill D., Taylor W. J., Terkeltaub R., Kuwabara M., Merriman T. R., Grainger R., Pineda C., Louthrenoo W., Edwards N. L., Andres M., Vargas-Santos A. B., Roddy E., Pascart T., Lin C. -T., Perez-Ruiz F., Tedeschi S. K., Kim S. C., Harrold L. R., McCarthy G., Kumar N., Chapman P., Tausche A. -K., Vazquez-Mellado J., Gutierrez M., da Rocha Castelar-Pinheiro G., Richette P., Pascual E., Fisher M. C., Burgos-Vargas R., Robinson P. C., Singh J. A., Jansen T. L., Saag K. G., Slot O., Uhlig T., Solomon D. H., Keenan R. T., Scire C. A., Biernat-Kaluza E., Dehlin M., Nuki G., Schlesinger N., Janssen M., Stamp L. K., Sivera F., Reginato A. M., Jacobsson L., Liote F., Ea H. -K., Rosenthal A., Bardin T., Choi H. K., Hershfield M. S., Czegley C., Choi S. J., Dalbeth N., Bursill, D, Taylor, W, Terkeltaub, R, Kuwabara, M, Merriman, T, Grainger, R, Pineda, C, Louthrenoo, W, Edwards, N, Andres, M, Vargas-Santos, A, Roddy, E, Pascart, T, Lin, C, Perez-Ruiz, F, Tedeschi, S, Kim, S, Harrold, L, Mccarthy, G, Kumar, N, Chapman, P, Tausche, A, Vazquez-Mellado, J, Gutierrez, M, da Rocha Castelar-Pinheiro, G, Richette, P, Pascual, E, Fisher, M, Burgos-Vargas, R, Robinson, P, Singh, J, Jansen, T, Saag, K, Slot, O, Uhlig, T, Solomon, D, Keenan, R, Scire, C, Biernat-Kaluza, E, Dehlin, M, Nuki, G, Schlesinger, N, Janssen, M, Stamp, L, Sivera, F, Reginato, A, Jacobsson, L, Liote, F, H. -K., E, Rosenthal, A, Bardin, T, Choi, H, Hershfield, M, Czegley, C, Choi, S, Dalbeth, N, Bursill D., Taylor W. J., Terkeltaub R., Kuwabara M., Merriman T. R., Grainger R., Pineda C., Louthrenoo W., Edwards N. L., Andres M., Vargas-Santos A. B., Roddy E., Pascart T., Lin C. -T., Perez-Ruiz F., Tedeschi S. K., Kim S. C., Harrold L. R., McCarthy G., Kumar N., Chapman P., Tausche A. -K., Vazquez-Mellado J., Gutierrez M., da Rocha Castelar-Pinheiro G., Richette P., Pascual E., Fisher M. C., Burgos-Vargas R., Robinson P. C., Singh J. A., Jansen T. L., Saag K. G., Slot O., Uhlig T., Solomon D. H., Keenan R. T., Scire C. A., Biernat-Kaluza E., Dehlin M., Nuki G., Schlesinger N., Janssen M., Stamp L. K., Sivera F., Reginato A. M., Jacobsson L., Liote F., Ea H. -K., Rosenthal A., Bardin T., Choi H. K., Hershfield M. S., Czegley C., Choi S. J., and Dalbeth N.

Abstract

Objective: The language currently used to describe gout lacks standardization. The aim of this project was to develop a consensus statement on the labels and definitions used to describe the basic disease elements of gout. Methods: Experts in gout (n = 130) were invited to participate in a Delphi exercise and face-to-face consensus meeting to reach consensus on the labeling and definitions for the basic disease elements of gout. Disease elements and labels in current use were derived from a content analysis of the contemporary medical literature, and the results of this analysis were used for item selection in the Delphi exercise and face-to-face consensus meeting. Results: There were 51 respondents to the Delphi exercise and 30 attendees at the face-to-face meeting. Consensus agreement (≥80%) was achieved for the labels of 8 disease elements through the Delphi exercise; the remaining 3 labels reached consensus agreement through the face-to-face consensus meeting. The agreed labels were monosodium urate crystals, urate, hyperuric(a)emia, tophus, subcutaneous tophus, gout flare, intercritical gout, chronic gouty arthritis, imaging evidence of monosodium urate crystal deposition, gouty bone erosion, and podagra. Participants at the face-to-face meeting achieved consensus agreement for the definitions of all 11 elements and a recommendation that the label “chronic gout” should not be used. Conclusion: Consensus agreement was achieved for the labels and definitions of 11 elements representing the fundamental components of gout etiology, pathophysiology, and clinical presentation. The Gout, Hyperuricemia, and Crystal-Associated Disease Network recommends the use of these labels when describing the basic disease elements of gout.

Published
2019

16. Subcutaneous Abatacept in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis

Author

Brunner H. I., Tzaribachev N., Vega-Cornejo G., Louw I., Berman A., Calvo Penades I., Anton J., Avila-Zapata F., Cuttica R., Horneff G., Foeldvari I., Keltsev V., Kingsbury D. J., Viola D. O., Joos R., Lauwerys B., Paz Gastanaga M. E., Rama M. E., Wouters C., Bohnsack J., Breedt J., Fischbach M., Lutz T., Minden K., Miraval T., Ally M. M. T. M., Rubio-Perez N., Solau Gervais E., van Zyl R., Li X., Nys M., Wong R., Banerjee S., Lovell D. J., Martini A., Ruperto N., Becker M. L., Ilowite N. T., Dare J. A., Morris P. K., Beukelman T. G., Wagner-Weiner L., Zemel L., Quartier P., Kone-Paut I., Belot A., Gerloni V., Ferrandiz M., Van Rensburg D. J., Scheibel I. M., Goldstein-Schainberg C., Silva C., Terreri M. T. S. E. L. A., Gamir M., Burgos Vargas R., Faugier Fuentes E., Cimaz R., Alessio M., Espada G., Brunner, H. I., Tzaribachev, N., Vega-Cornejo, G., Louw, I., Berman, A., Calvo Penades, I., Anton, J., Avila-Zapata, F., Cuttica, R., Horneff, G., Foeldvari, I., Keltsev, V., Kingsbury, D. J., Viola, D. O., Joos, R., Lauwerys, B., Paz Gastanaga, M. E., Rama, M. E., Wouters, C., Bohnsack, J., Breedt, J., Fischbach, M., Lutz, T., Minden, K., Miraval, T., Ally, M. M. T. M., Rubio-Perez, N., Solau Gervais, E., van Zyl, R., Li, X., Nys, M., Wong, R., Banerjee, S., Lovell, D. J., Martini, A., Ruperto, N., Becker, M. L., Ilowite, N. T., Dare, J. A., Morris, P. K., Beukelman, T. G., Wagner-Weiner, L., Zemel, L., Quartier, P., Kone-Paut, I., Belot, A., Gerloni, V., Ferrandiz, M., Van Rensburg, D. J., Scheibel, I. M., Goldstein-Schainberg, C., Silva, C., Terreri, M. T. S. E. L. A., Gamir, M., Burgos Vargas, R., Faugier Fuentes, E., Cimaz, R., Alessio, M., and Espada, G.

Subjects
Male, musculoskeletal diseases, 0301 basic medicine, medicine.medical_specialty, Adolescent, genetic structures, Immunology, Juvenile, Arthritis, Injections, Subcutaneou, Abatacept, Arthritis, Juvenile, Child, Child, Preschool, Cohort Studies, Female, Humans, Immunosuppressive Agents, Injections, Subcutaneous, Treatment Outcome, Injections, Immunosuppressive Agent, 03 medical and health sciences, 0302 clinical medicine, Rheumatology, Pharmacokinetics, Open label study, medicine, Immunology and Allergy, In patient, Preschool, skin and connective tissue diseases, 030203 arthritis & rheumatology, business.industry, Subcutaneous, medicine.disease, Dermatology, Clinical trial, 030104 developmental biology, Methotrexate, Cohort Studie, business, Human, medicine.drug
Abstract

Objective: To investigate the pharmacokinetics, effectiveness, and safety of subcutaneous (SC) abatacept treatment over 24 months in patients with polyarticular-course juvenile idiopathic arthritis (JIA). Methods: In this phase III, open-label, international, multicenter, single-arm study, patients with polyarticular JIA (cohort 1, ages 6–17 years and cohort 2, ages 2–5 years) in whom treatment with ≥1 disease-modifying antirheumatic drug was unsuccessful received weight-tiered SC abatacept weekly: 10 to

Published
2018
Full Text
View/download PDF

19. OP0047 IDENTIFICATION OF CLINICAL PHENOTYPES IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS, PERIPHERAL SPONDYLOARTHRITIS AND PSORIATIC ARTHRITIS ACCORDING TO PERIPHERAL MUSCULOSKELETAL MANIFESTATIONS: A CLUSTER ANALYSIS IN THE INTERNATIONAL ASAS-PERSPA STUDY

Author

López-Medina, C., primary, Chevret, S., additional, Moltó, A., additional, Sieper, J., additional, Duruöz, M. T., additional, Kiltz, U., additional, Zorkany, B., additional, Hajjaj-Hassouni, N., additional, Burgos-Vargas, R., additional, Maldonado-Cocco, J., additional, Ziade, N., additional, Gavali, M., additional, Navarro-Compán, V., additional, Luo, S. F., additional, Biglia, A., additional, Kim, T. J., additional, Kishimoto, M., additional, Pimentel Dos Santos, F., additional, Gu, J., additional, Muntean, L., additional, Van Gaalen, F. A., additional, Géher, P., additional, Magrey, M., additional, Ibáñez, S., additional, Bautista-Molano, W., additional, Maksymowych, W. P., additional, Machado, P. M., additional, Landewé, R. B. M., additional, Van der Heijde, D., additional, and Dougados, M., additional

Published
2021
Full Text
View/download PDF

20. Efficacy and Safety of Tocilizumab for Polyarticular-Course Juvenile Idiopathic Arthritis in the Open-Label 2-Year Extension of a Phase 3 Trial

Author

Brunner HI, Ruperto N, Zuber Z, Cuttica R, Keltsev V, Xavier RM, Burgos-Vargas R, Calvo Penades I, Silverman ED, Espada G, Ferrandiz Zavaler M, Kimura Y, Duarte C, Job-Deslandre C, Joos R, Douglass W, Wimalasundera S, Bharucha KN, Wells C, Lovell DJ, Martini A, De Benedetti F, and Paediatric Rheumatology International Trials Organisation (PRINTO), the Pediatri

Subjects
musculoskeletal diseases, skin and connective tissue diseases, Biologicals, clinical trial, juvenile idiopathic arthritis, pediatric rheumatology
Abstract

Report the 2-year efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis (pcJIA).

Published
2020

21. Prévalence et distribution des manifestations périphériques musculosquelettiques chez les patients atteints de spondyloarthrite (en incluant le rhumatisme psoriasique) : résultats de l’étude transversale internationale ASAS-PerSpA

Author

Lopez-Medina, C., primary, Molto, A., additional, Sieper, J., additional, Duruöz, T., additional, Kiltz, U., additional, Elzorkany, B., additional, Hajjaj-Hassouni, N., additional, Burgos-Vargas, R., additional, Maldonado-Cocco, J., additional, Ziade, N., additional, Gavali, M., additional, Navarro-Compán, V., additional, Luo, S.F., additional, Monti, S., additional, Kim, T.J., additional, Kishimoto, M., additional, Pimentel-Santos, F., additional, Gu, J., additional, Schiotis, R., additional, Van Gaalen, F., additional, Géher, P., additional, Magrey, M., additional, Ibañez, S., additional, Bautista-Molano, W., additional, Maksymowych, W., additional, Machado, P., additional, Landewé, R., additional, Van Der Heijde, D., additional, and Dougados, M., additional

Published
2020
Full Text
View/download PDF

22. Effet du sécukinumab sur la réduction des synovites évaluée par échographie Doppler puissance chez des patients atteints de rhumatisme psoriasique actif et naïfs de biothérapie : résultats d’une étude de phase 3 randomisée et contrôlée par placebo

Author

D’Agostino, M.A., primary, Schett, G., additional, Lopez Rodriguez, A., additional, Senolt, L., additional, Maldonado-Cocco, J., additional, Burgos-Vargas, R., additional, Naredo, E., additional, Carron, P., additional, Boers, M., additional, Duggan, A.M., additional, Goyanka, P., additional, and Gaillez, C., additional

Published
2020
Full Text
View/download PDF

23. Identification des phénotypes cliniques selon les manifestations périphériques musculosquelettiques chez des patients atteints de spondyloarthrite (en incluant le rhumatisme psoriasique) : une analyse de clusters dans l’étude internationale ASAS-PerSpA

Author

Lopez-Medina, C., primary, Chevret, S., additional, Molto, A., additional, Sieper, J., additional, Duruöz, T., additional, Kiltz, U., additional, Elzorkany, B., additional, Hajjaj-Hassouni, N., additional, Burgos-Vargas, R., additional, Maldonado-Cocco, J., additional, Ziade, N., additional, Gavali, M., additional, Navarro-Compán, V., additional, Luo, S.F., additional, Biglia, A., additional, Kim, T.J., additional, Kishimoto, M., additional, Pimentel-Santos, F., additional, Gu, J., additional, Muntean, L., additional, Van Gaalen, F., additional, Géher, P., additional, Magrey, M., additional, Ibañez, S., additional, Bautista-Molano, W., additional, Maksymowych, W., additional, Machado, P., additional, Landewé, R., additional, Van Der Heijde, D., additional, and Dougados, M., additional

Published
2020
Full Text
View/download PDF

24. Juvenile onset spondyloarthropathies: therapeutic aspects. (Extended Report)

Author

Burgos-Vargas, R.

Subjects
Children -- Diseases, Inflammation -- Care and treatment -- Physiological aspects -- Research, Spondyloarthropathies -- Physiological aspects -- Research -- Care and treatment, Family and marriage, Health, Diseases, Care and treatment, Physiological aspects, Research
Abstract

Juvenile onset spondyloarthropathy (SpA) is a term that refers to a group of human leucocyte antigen (HLA).B27 associated inflammatory disorders affecting children under the age of 16 years, producing a [...]

Published
2003

25. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis

Author

Braun, J, van den Berg, R, Baraliakos, X, Boehm, H, Burgos-Vargas, R, Collantes-Estevez, E, Dagfinrud, H, Dijkmans, B, Dougados, M, Emery, P, Geher, P, Hammoudeh, M, Inman, RD, Jongkees, M, Khan, MA, Kiltz, U, Kvien, TK, Leirisalo-Repo, M, Maksymowych, WP, Olivieri, I, Pavelka, K, Sieper, J, Stanislawska-Biernat, E, Wendling, D, Özgocmen, S, van Drogen, C, van Royen, BJ, and van der Heijde, D

Published
2011
Full Text
View/download PDF

26. The efficacy and safety of abatacept in patients with non–life-threatening manifestations of systemic lupus erythematosus: Results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial

Author

Merrill, J. T., Burgos-Vargas, R., Westhovens, R., Chalmers, A., DʼCruz, D., Wallace, D. J., Bae, S. C., Sigal, L., Becker, J.-C., Kelly, S., Raghupathi, K., Li, T., Peng, Y., Kinaszczuk, M., and Nash, P.

Published
2010
Full Text
View/download PDF

30. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal

Author

Rudwaleit, M, Landewé, R, van der Heijde, D, Listing, J, Brandt, J, Braun, J, Burgos-Vargas, R, Collantes-Estevez, E, Davis, J, Dijkmans, B, Dougados, M, Emery, P, van der Horst-Bruinsma, I E, Inman, R, Khan, M A, Leirisalo-Repo, M, van der Linden, S, Maksymowych, W P, Mielants, H, Olivieri, I, Sturrock, R, de Vlam, K, and Sieper, J

Published
2009
Full Text
View/download PDF

37. Health-related quality of life of patients with juvenile idiopathic arthritis coming from 3 different geographic areas. The PRINTO multinational quality of life cohort study

Author

Gutiérrez-Suárez, R., Pistorio, A., Cruz, A. Cespedes, Norambuena, X., Flato, B., Rumba, I., Harjacek, M., Nielsen, S., Susic, G., Mihaylova, D., Huemer, C., Melo-Gomes, J., Andersson-Gare, B., Balogh, Z., De Cunto, C., Vesely, R., Pagava, K., Romicka, A. M., Burgos-Vargas, R., Martini, A., and Ruperto, N.

Published
2007

43. ASAS/EULAR recommendations for the management of ankylosing spondylitis

Author

Zochling, J, van der Heijde, D, Burgos-Vargas, R, Collantes, E, Davis, J C, Jr, Dijkmans, B, Dougados, M, Géher, P, Inman, R D, Khan, M A, Kvien, T K, Leirisalo-Repo, M, Olivieri, I, Pavelka, K, Sieper, J, Stucki, G, Sturrock, R D, van der Linden, S, Wendling, D, Böhm, H, van Royen, B J, and Braun, J

Published
2006

44. Phenotypic variability and disparities in treatment and outcomes of childhood arthritis throughout the world: an observational cohort study

Author

Consolaro, A, Giancane, G, Alongi, A, van Dijkhuizen, Ehp, Aggarwal, A, Al-Mayouf, Sm, Bovis, F, De Inocencio, J, Demirkaya, E, Flato, B, Foell, D, Garay, Sm, Lazăr, C, Lovell, Dj, Montobbio, C, Miettunen, P, Mihaylova, D, Nielsen, S, Orban, I, Rumba-Rozenfelde, I, Magalhães, C, Shafaie, N, Susic, G, Trachana, M, Wulffraat, N, Pistorio, A, Martini, A, Ruperto, N, Ravelli, A &amp, Abdwani R, Aghighi, Y, Aiche, Mf, Ailioaie, C, Aktay Ayaz, N, Al-Abrawi, S, Alexeeva, E, Anton, J, Apostol, A, Arguedas, O, Avcin, T, Barone, P, Berntson, L, Boteanu, Al, Boyko, Y, Burgos-Vargas, R, Calvo Penades, I, Chédeville, G, Cimaz, R, Civino, A, Consolini, R, Constantin, T, Cuttica, R, Dallos, T, Martin, N, Magni-Manzoni, S, De Cunto, C, Dolezalova, P, Ekelund, M, El Miedany, Y, Espada, G, Estmann Christensen, A, Foeldvari, I, Gallizzi, R, Ganser, G, Gerloni, V, Haas, Jp, Harel, L, Harjacek, M, Hashad, S, Herlin, T, Herrera, C, Hofer, M, Holzinger, D, Horneff, G, Huppertz, Hi, Iagăru, N, Ibanez Estrella, A, Ioseliani, M, Joos, R, Knupp Oliveira, S, Kamphuis, S, Kasapcopur, O, Katsicas, Mm, Khubchandani, R, Kondi, A, Kröger, L, La Torre, F, Laday, M, Lahdenne, P, Maggio, Mc, Magnolia, Mg, Malagon, C, Malin, M, Martino, S, Melo-Gomes, Ja, Mesa-Del-Castillo, P, Militaru, A, Minden, K, Miniaci, A, Moradinejad, Mh, Morel Ayala, Z, Nikishina, I, Norambuena, X, Nordal, Eb, Pagava, K, Panaviene, V, Pastore, S, Pieropan, S, Podda, Ra, Pruunsild, C, Putto-Laurila, A, Quartier, P, Remesal, A, Rigante, Donato, Ringold, S, Rutkowska-Sak, L, Rygg, M, Saurenmann, Rk, Sawhney, S, Scott, C, Shiari, R, Smolewska, E, Sozeri, B, Swart, Jf, Sztajnbok, F, Torcoletti, M, Tsitsami, E, Tzaribachev, N, Unsal, E, Uziel, Y, Vähäsalo, P, Varbanova, B, Vargova, V, Vesely, R, Vijatov-Djuric, G, Vilaiyuk, S, Vojinovic, J, Vougiouka, O, Weiss, P, Wouters, C, Rigante D (ORCID:0000-0001-7032-7779), Consolaro, A, Giancane, G, Alongi, A, van Dijkhuizen, Ehp, Aggarwal, A, Al-Mayouf, Sm, Bovis, F, De Inocencio, J, Demirkaya, E, Flato, B, Foell, D, Garay, Sm, Lazăr, C, Lovell, Dj, Montobbio, C, Miettunen, P, Mihaylova, D, Nielsen, S, Orban, I, Rumba-Rozenfelde, I, Magalhães, C, Shafaie, N, Susic, G, Trachana, M, Wulffraat, N, Pistorio, A, Martini, A, Ruperto, N, Ravelli, A &amp, Abdwani R, Aghighi, Y, Aiche, Mf, Ailioaie, C, Aktay Ayaz, N, Al-Abrawi, S, Alexeeva, E, Anton, J, Apostol, A, Arguedas, O, Avcin, T, Barone, P, Berntson, L, Boteanu, Al, Boyko, Y, Burgos-Vargas, R, Calvo Penades, I, Chédeville, G, Cimaz, R, Civino, A, Consolini, R, Constantin, T, Cuttica, R, Dallos, T, Martin, N, Magni-Manzoni, S, De Cunto, C, Dolezalova, P, Ekelund, M, El Miedany, Y, Espada, G, Estmann Christensen, A, Foeldvari, I, Gallizzi, R, Ganser, G, Gerloni, V, Haas, Jp, Harel, L, Harjacek, M, Hashad, S, Herlin, T, Herrera, C, Hofer, M, Holzinger, D, Horneff, G, Huppertz, Hi, Iagăru, N, Ibanez Estrella, A, Ioseliani, M, Joos, R, Knupp Oliveira, S, Kamphuis, S, Kasapcopur, O, Katsicas, Mm, Khubchandani, R, Kondi, A, Kröger, L, La Torre, F, Laday, M, Lahdenne, P, Maggio, Mc, Magnolia, Mg, Malagon, C, Malin, M, Martino, S, Melo-Gomes, Ja, Mesa-Del-Castillo, P, Militaru, A, Minden, K, Miniaci, A, Moradinejad, Mh, Morel Ayala, Z, Nikishina, I, Norambuena, X, Nordal, Eb, Pagava, K, Panaviene, V, Pastore, S, Pieropan, S, Podda, Ra, Pruunsild, C, Putto-Laurila, A, Quartier, P, Remesal, A, Rigante, Donato, Ringold, S, Rutkowska-Sak, L, Rygg, M, Saurenmann, Rk, Sawhney, S, Scott, C, Shiari, R, Smolewska, E, Sozeri, B, Swart, Jf, Sztajnbok, F, Torcoletti, M, Tsitsami, E, Tzaribachev, N, Unsal, E, Uziel, Y, Vähäsalo, P, Varbanova, B, Vargova, V, Vesely, R, Vijatov-Djuric, G, Vilaiyuk, S, Vojinovic, J, Vougiouka, O, Weiss, P, Wouters, C, and Rigante D (ORCID:0000-0001-7032-7779)

Abstract

BACKGROUND: To our knowledge, the characteristics and burden of childhood arthritis have never been studied on a worldwide basis. We aimed to investigate, with a cross-sectional study, the prevalence of disease categories, treatment methods, and disease status in patients from across different geographical areas and from countries with diverse wealth status. METHODS: In this multinational, cross-sectional, observational cohort study, we asked international paediatric rheumatologists from specialised centres to enrol children with a diagnosis of juvenile idiopathic arthritis, according to International League of Associations for Rheumatology criteria, who were seen consecutively for a period of 6 months. Each patient underwent retrospective and cross-sectional assessments, including measures of disease activity and damage and questionnaires on the wellbeing and quality of life of the children. We qualitatively compared the collected data across eight geographical areas, and we explored an association between disease activity and damage and a country's gross domestic product (GDP) with a multiple logistic regression analysis. FINDINGS: Between April 4, 2011, and Nov 21, 2016, 9081 patients were enrolled at 130 centres in 49 countries, grouped into eight geographical areas. Systemic arthritis (125 [33·0%] of 379 patients) and enthesitis-related arthritis (113 [29·8%] of 379) were more common in southeast Asia, whereas oligoarthritis was more prevalent in southern Europe (1360 [56·7%] of 2400) and rheumatoid factor-negative polyarthritis was more frequent in North America (165 [31·5%] of 523) than in the other areas. Prevalence of uveitis was highest in northern Europe (161 [19·1%] of 845 patients) and southern Europe (450 [18·8%] of 2400) and lowest in Latin America (54 [6·4%] of 849), Africa and Middle East (71 [5·9%] of 1209), and southeast Asia (19 [5·0%] of 379). Median age at disease onset was lower in southern Europe (3·5 years, IQR 1·9-7·3) than in other regions

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results